MX373965B - Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). - Google Patents

Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).

Info

Publication number
MX373965B
MX373965B MX2015011281A MX2015011281A MX373965B MX 373965 B MX373965 B MX 373965B MX 2015011281 A MX2015011281 A MX 2015011281A MX 2015011281 A MX2015011281 A MX 2015011281A MX 373965 B MX373965 B MX 373965B
Authority
MX
Mexico
Prior art keywords
prevention
treatment
hae
inhibition
esterase inhibitor
Prior art date
Application number
MX2015011281A
Other languages
English (en)
Spanish (es)
Other versions
MX2015011281A (es
Inventor
Cynthia Gallagher
Mark Cornell Manning
Steven Ruddy
Original Assignee
Viropharma Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373965(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Biologics Llc filed Critical Viropharma Biologics Llc
Publication of MX2015011281A publication Critical patent/MX2015011281A/es
Publication of MX373965B publication Critical patent/MX373965B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2015011281A 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). MX373965B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (2)

Publication Number Publication Date
MX2015011281A MX2015011281A (es) 2016-03-03
MX373965B true MX373965B (es) 2020-07-13

Family

ID=51538486

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015011281A MX373965B (es) 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
MX2020004724A MX389449B (es) 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020004724A MX389449B (es) 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Country Status (30)

Country Link
US (9) US9616111B2 (enExample)
EP (3) EP3290046B1 (enExample)
JP (9) JP6184581B2 (enExample)
KR (4) KR20210021146A (enExample)
CN (2) CN111529708A (enExample)
AU (3) AU2014232912A1 (enExample)
BR (1) BR112015023207A8 (enExample)
CA (2) CA2904543C (enExample)
CY (2) CY1119419T1 (enExample)
DE (1) DE202014011208U1 (enExample)
DK (2) DK3290046T3 (enExample)
EA (1) EA201591278A1 (enExample)
ES (2) ES2639833T3 (enExample)
GB (1) GB2530921B (enExample)
HK (1) HK1250912B (enExample)
HR (2) HRP20171269T1 (enExample)
HU (2) HUE041837T2 (enExample)
IL (2) IL241549B (enExample)
LT (2) LT3290046T (enExample)
ME (2) ME02865B (enExample)
MX (3) MX373965B (enExample)
PL (2) PL3290046T3 (enExample)
PT (2) PT3290046T (enExample)
RS (2) RS58351B1 (enExample)
SG (2) SG11201507616VA (enExample)
SI (2) SI2968434T1 (enExample)
SM (2) SMT201700415T1 (enExample)
TR (1) TR201900319T4 (enExample)
WO (1) WO2014145519A2 (enExample)
ZA (3) ZA201507604B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171269T1 (hr) 2013-03-15 2017-11-03 Shire Viropharma Incorporated C1-inh pripravci za upotrebu za prevenciju i liječenje nasljednog angioedema (hae)
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
SG11201706019XA (en) * 2015-02-20 2017-09-28 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
EP3493832A1 (en) * 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
CA3034568A1 (en) * 2016-08-23 2018-03-01 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
US20200390872A1 (en) 2018-02-28 2020-12-17 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US12397054B2 (en) 2018-06-22 2025-08-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
JPWO2019245039A1 (ja) 2018-06-22 2021-06-24 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 感染性免疫寛容を惹起するための組成物
WO2019245037A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法
EP4079325A1 (en) * 2019-12-16 2022-10-26 Nipro Corporation Aggregation inhibitory agent and medical composition and medical device including same
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
ATE212859T1 (de) * 1993-09-01 2002-02-15 Sanquin Bloedvoorziening C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
AU1042597A (en) 1995-12-18 1997-07-14 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DE60132169T2 (de) 2000-01-31 2008-12-11 Pharming Intellectual Property Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
EP1626736B1 (en) 2003-05-16 2020-09-16 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
KR20190045414A (ko) 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2777845C (en) 2009-10-16 2017-08-01 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
AU2012311483B2 (en) 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
US9452203B2 (en) 2011-12-22 2016-09-27 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
EP2825204A1 (en) 2012-03-16 2015-01-21 Belrose Pharma Inc. Polymeric conjugates of c-1 inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
HRP20171269T1 (hr) * 2013-03-15 2017-11-03 Shire Viropharma Incorporated C1-inh pripravci za upotrebu za prevenciju i liječenje nasljednog angioedema (hae)
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
SG11201507616VA (en) 2015-10-29
ZA201706929B (en) 2019-05-29
KR20150135242A (ko) 2015-12-02
AU2020203183A1 (en) 2020-06-04
US10105423B2 (en) 2018-10-23
HUE041837T2 (hu) 2019-05-28
JP2018119001A (ja) 2018-08-02
JP6877472B2 (ja) 2021-05-26
AU2018229558A1 (en) 2018-10-04
EP3508213A1 (en) 2019-07-10
US20160015795A1 (en) 2016-01-21
US9616111B2 (en) 2017-04-11
CN105517559A (zh) 2016-04-20
SMT201700415T1 (it) 2017-11-15
GB2530921A (en) 2016-04-06
EP3290046A1 (en) 2018-03-07
MX2020004724A (es) 2022-01-18
HRP20190270T1 (hr) 2019-04-05
US20190160157A1 (en) 2019-05-30
IL241549B (en) 2020-08-31
ZA201507604B (en) 2018-05-30
WO2014145519A2 (en) 2014-09-18
JP2018119000A (ja) 2018-08-02
DK3290046T3 (en) 2019-03-18
MX2015011281A (es) 2016-03-03
ES2639833T3 (es) 2017-10-30
KR102579789B1 (ko) 2023-09-15
CA2904543A1 (en) 2014-09-18
ES2713004T3 (es) 2019-05-17
BR112015023207A2 (pt) 2017-11-21
AU2020203183B2 (en) 2022-06-02
CA3054718A1 (en) 2014-09-18
CY1119419T1 (el) 2018-03-07
US11534482B2 (en) 2022-12-27
IL276153B (en) 2022-06-01
KR102430453B1 (ko) 2022-08-05
PL3290046T3 (pl) 2019-05-31
IL276153A (en) 2020-09-30
CY1121653T1 (el) 2020-07-31
BR112015023207A8 (pt) 2018-01-23
US20190160158A1 (en) 2019-05-30
LT3290046T (lt) 2019-03-12
GB201519921D0 (en) 2015-12-23
KR20220070049A (ko) 2022-05-27
PT2968434T (pt) 2017-09-18
JP6473536B2 (ja) 2019-02-20
WO2014145519A3 (en) 2014-12-31
EA201591278A1 (ru) 2016-03-31
JP6422520B2 (ja) 2018-11-14
GB2530921B (en) 2017-09-20
NZ751555A (en) 2021-07-30
US20170224788A1 (en) 2017-08-10
JP2017105847A (ja) 2017-06-15
US20180110844A1 (en) 2018-04-26
DE202014011208U1 (de) 2018-08-23
SMT201900141T1 (it) 2019-05-10
KR20210021146A (ko) 2021-02-24
JP6877471B2 (ja) 2021-05-26
JP2019073546A (ja) 2019-05-16
RS58351B1 (sr) 2019-03-29
US10080788B2 (en) 2018-09-25
PT3290046T (pt) 2019-02-18
SI2968434T1 (sl) 2017-11-30
US20200261556A1 (en) 2020-08-20
JP6473534B2 (ja) 2019-02-20
EP2968434A4 (en) 2016-03-02
AU2014232912A1 (en) 2015-09-03
HUE036224T2 (hu) 2018-06-28
JP2019073544A (ja) 2019-05-16
US20180085441A1 (en) 2018-03-29
ME02865B (me) 2018-04-20
HK1250912B (en) 2020-01-10
HRP20171269T1 (hr) 2017-11-03
JP2016516073A (ja) 2016-06-02
JP6184581B2 (ja) 2017-08-23
PL2968434T3 (pl) 2018-01-31
ZA201806793B (en) 2020-01-29
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
SG10201707598QA (en) 2017-10-30
MX389449B (es) 2025-03-20
EP2968434A2 (en) 2016-01-20
CA2904543C (en) 2019-10-08
KR20210129267A (ko) 2021-10-27
US20180153972A1 (en) 2018-06-07
AU2018229558B2 (en) 2020-03-05
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
TR201900319T4 (tr) 2019-02-21
DK2968434T3 (en) 2017-09-11
JP6473535B2 (ja) 2019-02-20
EP2968434B1 (en) 2017-06-28
LT2968434T (lt) 2017-09-25
HK1220403A1 (en) 2017-05-05
ME03326B (me) 2019-10-20
JP2019073545A (ja) 2019-05-16
JP2021088599A (ja) 2021-06-10
MX2021011946A (es) 2021-11-17
SI3290046T1 (sl) 2019-04-30
CN111529708A (zh) 2020-08-14
JP2018119002A (ja) 2018-08-02
EP3290046B1 (en) 2019-01-02
US11364288B2 (en) 2022-06-21
JP6877470B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
MX373965B (es) Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
BR112017006664A2 (pt) terapias de combinação
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2014055996A3 (en) Rho kinase inhibitors
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX372858B (es) Sistemas y métodos de tratamiento de agua.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
IL259691A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA2986759C (en) AUTOTAXIN INHIBITORS AND THEIR USES
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
EP3220917A4 (en) Compositions for treating acute, post-operative, or chronic pain and methods of using the same
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit

Legal Events

Date Code Title Description
FG Grant or registration